| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. |
|
Medicine details |
|
| Medicine name | nilotinib (Tasigna®) |
| Formulation | 150 mg capsule |
| Reference number | 428 |
| Indication | Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in the chronic phase |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/03/2011 |
| NICE guidance | TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |